picroside I: RN given for (1aS-(1aalpha,1bbeta,2beta(E),5abeta,6beta,6aalpha))-isomer; hepatoprotective agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6440892 |
| CHEMBL ID | 454577 |
| MeSH ID | M0283615 |
| Synonym |
|---|
| picroside i |
| CHEMBL454577 |
| 27409-30-9 |
| beta-d-glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, 6-(3-phenyl-2-propenoate), (1as-(1aalpha,1bbeta,2beta(e),5abeta,6beta,6aalpha))- |
| einecs 248-445-1 |
| S3787 |
| AKOS015896740 |
| picroside-i |
| picrosidei |
| [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[[(1s,2s,4s,5s,6r,10s)-5-hydroxy-2-(hydroxymethyl)-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-10-yl]oxy]oxan-2-yl]methyl (e)-3-phenylprop-2-enoate |
| HY-N0407 |
| CS-0008939 |
| CCG-269629 |
| AS-56345 |
| amphicoside i |
| DTXSID101318188 |
| P2593 |
| mfcd29505480 |
Picroside I is an iridoid glycoside derived from Picrorhiza kurroa Royle ex Benth and PicrorHiza scrophulariiflora Pennell. Picro side I is a major active constituent of picroliv.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Picroside I is an iridoid glycoside derived from Picrorhiza kurroa Royle ex Benth and Picrorhiza scrophulariiflora Pennell and characterized by many biological activities. " | ( Metabolic profiles and pharmacokinetics of picroside I in rats by liquid chromatography combined with electrospray ionization tandem mass spectrometry. Han, H; Ju, Z; Wang, Z; Xiong, K; Zhang, T, 2018) | 2.19 |
| "Picroside I is a major active constituent of picroliv." | ( Sensitive high-performance liquid chromatographic assay method for the determination of picroside I in plasma. Dwivedi, AK; Kulkarni, D; Singh, S, 1997) | 1.24 |
The validated method was successfully applied for the pharmacokinetic analysis of picroside I in rats after oral administration. The study was designed to check metabolic (in vitro and in vivo) profile along with pharmacokinetics profile of pmicroside I and II.
| Excerpt | Reference | Relevance |
|---|---|---|
| "05) in oral bioavailability of picrosides I and II from different preparations." | ( Comparative pharmacokinetic profiles of picrosides I and II from kutkin, Picrorhiza kurroa extract and its formulation in rats. Anandjiwala, S; Dash, RP; Nivsarkar, M; Upadhyay, D, 2013) | 0.39 |
| " Previously, we have reported that oral bioavailability of picroside I and II is low." | ( In vitro - In vivo metabolism and pharmacokinetics of picroside I and II using LC-ESI-MS method. Anandjiwala, S; Nivsarkar, M; Padh, H; Upadhyay, D, 2016) | 0.93 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID401472 | Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.1 mg/ml after 30 hrs relative to control | |||
| AID775065 | Antimalarial activity against ring stage of Plasmodium falciparum 3D7 infected in erythrocytes assessed as [3H]-hypoxanthine incorporation after 48 hrs by liquid scintillation counting analysis | 2013 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21 | Chemical investigation of an antimalarial Chinese medicinal herb Picrorhiza scrophulariiflora. |
| AID401473 | Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 mg/ml after 30 hrs relative to control | |||
| AID401475 | Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.1 mg/ml after 30 hrs | |||
| AID401471 | Antihepatotoxic activity against 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.01 mg/ml after 30 hrs relative to control | |||
| AID401474 | Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 0.01 mg/ml after 30 hrs | |||
| AID401476 | Cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 mg/ml after 30 hrs | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 6 (18.18) | 29.6817 |
| 2010's | 20 (60.61) | 24.3611 |
| 2020's | 6 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.88) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 36 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||